EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Crosstalk Between Opioids and the Anti-Tumour Immune Checkpoint Axis

Parsa Alan, Marie-Odile Parat iD

Current Oncology · 09.07.2026 · 33 (7) · 411

DOI: 10.3390/curroncol33070411 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 09.07.2026. Verfasst von Parsa Alan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia. Hauptthemen laut MEDLINE: Analgesics, Opioid, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opioids are frequently prescribed for cancer pain management, yet accumulating evidence suggests that opioid exposure may be associated with inferior outcomes in patients also undergoing treatment with immune checkpoint inhibitors (ICIs). To synthesize mechanistic and clinical evidence linking opioids to the PD-1/PD-L1 axis, the literature was searched up to 18 January 2026, with study selection and data extraction focused on (i) cancer-cell and immune-cell effects of opioid agonism or antagonism on PD-1/PD-L1 biology, and (ii) clinical studies reporting ICI outcomes (progression-free survival, overall survival, or treatment duration) with concomitant opioid exposure. Preclinical studies support multiple, non-mutually exclusive mechanisms: opioids can induce PD-L1 in tumour cells, modulate innate-inflammatory pathways (including TLR4-linked cascades), promote dysfunctional T-cell phenotypes that reduce responsiveness to PD-1 blockade, and show context- and opioid-dependent effects. Clinical cohorts and meta-analytic datasets in non-small cell lung cancer and other tumour types report associations between opioid exposure (including higher morphine-equivalent dosing) and worse ICI outcomes. The intersection of opioid signaling with PD-1/PD-L1 biology likely operates across cancer cell-intrinsic and immune cell-intrinsic pathways, providing a mechanistic rationale for prospective evaluation of opioid-sparing strategies and/or peripheral opioid antagonism as adjuncts to checkpoint blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidImmune Checkpoint InhibitorsNeoplasmsHumansAnimals

Stichwörter der Autor:innen

PD-1PD-L1immune checkpoint inhibitorsopioid

Substanzen

Analgesics, OpioidImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia.
  • School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Brisbane, QLD 4102, Australia.

ORCID-Profile: Marie-Odile Parat

Zitieren

APA

Alan, P., & Parat, M. O. (2026). Crosstalk Between Opioids and the Anti-Tumour Immune Checkpoint Axis. Current Oncology, 33(7), 411. https://doi.org/10.3390/curroncol33070411

Vancouver

Alan P, Parat MO. Crosstalk Between Opioids and the Anti-Tumour Immune Checkpoint Axis. Current Oncology. 2026;33(7):411. doi:10.3390/curroncol33070411

BibTeX
@article{Alan2026,
  author = {Alan, Parsa and Parat, Marie-Odile},
  title = {Crosstalk Between Opioids and the Anti-Tumour Immune Checkpoint Axis},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {7},
  pages = {411},
  doi = {10.3390/curroncol33070411}
}
Kostenlos starten →